What we do

We have built our AI-enabled drug discovery engine, the Benevolent Platform™, to drive a revolution in drug discovery – from target identification through to clinical development.

THE BENEVOLENT PLATFORM™

A versatile, scalable and proven AI drug discovery engine

Comprehensive data foundations

We integrate data from across domains and data types, including ’omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology.

Biology first

Our technology empowers scientists to access an ever-expanding data landscape and map the underlying biology of complex multifactorial diseases in unprecedented detail.

Hypothesis driven

Scientists use our tools to navigate disease networks to gain a comprehensive understanding of biological effects, refine hypotheses and predict high-confidence targets.

What We do - Wet Labs.jpg

WET LABS AND AI CHEMISTRY

AI chemistry and in-house wet labs reduce development timelines

We can validate high-quality drug targets generated by the Benevolent Platform™ in our fully equipped laboratories in Cambridge (UK), where we have cutting-edge technologies such as CRISPR, RNA-seq and human iPSCs to evaluate target hypotheses in cell-based models. 

Pipeline

BENEFITS

Proven to enhance drug discovery

Benefit-1.svg
DISEASE AGNOSTIC

We can work on any therapeutic area due to the breadth and diversity of our data foundations.

Benefit-2.svg
MODALITY AGNOSTIC

The Benevolent Platform™ can be applied to antibody and biologic targets, in addition to small molecule targets, to further diversify our portfolio.

Benefit-3.svg
IDENTIFIES NOVEL TARGETS

Our predictive tools can surface targets that have never been considered for a disease before – and spark creativity in scientists.

Benefit-4.svg
ACCELERATES DISCOVERY

Through the combined capabilities of our AI Platform, scientific expertise and wet lab facilities we can rapidly identify and validate targets and reduce drug development timelines.

Benefit-5.svg
BUILT FOR SCALE

Our scalable, repeatable approach can support multiple in-house drug programmes and commercial collaborations.

Benefit-6.svg
POTENTIAL TO INCREASE PROBABILITY OF SUCCESS

Scientists use our tools to build higher confidence hypotheses in the earliest stages of drug discovery, with the aim of reducing costly failures down the line.